Osteopontin is a useful predictor of bone metastasis and survival in patients with locally advanced nasopharyngeal carcinoma

International Journal of Cancer

Volumn 137, Issue 7, 2015, Pages 1672-1678

  Hou, Xue ^a,b   Wu, Xuan ^c   Huang, Peiyu ^a,b   Zhan, Jianhua ^a,b   Zhou, Ting ^a,b   Ma, Yuxiang ^a,b   Qin, Tao ^a,b   Luo, Rongzhen ^a,b   Feng, Yanfen ^a,b   Xu, Ying ^d   Chen, Likun ^a,b   Zhang, Li ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Department of Colorectal Surgery   (China)

^c PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

bone metastasis; bone sialoprotein; nasopharyngeal neoplasms; osteopontin; prognosis

Indexed keywords

BONE SIALOPROTEIN; OSTEOPONTIN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; NASOPHARYNX CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR CLASSIFICATION; BONE TUMOR; METABOLISM; MIDDLE AGED; NASOPHARYNX TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; SECONDARY; YOUNG ADULT;

ADULT; BONE NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN-BINDING SIALOPROTEIN; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84943369787     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29540     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, et al., Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Razak AR, Siu LL, Liu FF, et al., Nasopharyngeal carcinoma: the next challenges. Eur J Cancer 2010; 46: 1967-78.
3. Stiller CA,. International patterns of cancer incidence in adolescents. Cancer Treat Rev 2007; 33: 631-45.
4. Lee AW, Lin JC, Ng WT,. Current management of nasopharyngeal cancer. Semin Radiat Oncol 2012; 22: 233-44.
5. Baujat B, Audry H, Bourhis J, et al., Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006; 64: 47-56.
6. Wolden SL, Chen WC, Pfister DG, et al., Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006; 64: 57-62.
7. Lee AW, Sze WM, Au JS, et al., Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2005; 61: 1107-16.
8. Peng X, Chen S, Du C, et al., Clinical features and prognostic factors in patients with nasopharyngeal carcinoma relapse after primary treatment. Head Neck Oncol 2013; 5: 21.
9. Pan CC, Lu J, Chen P, et al., Evaluation of the prognostic significance of refinement and stratification of distant metastasis status in 1016 cases of nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Zhi 2013; 35: 595-9.
10. Bellahcene A, Castronovo V, Ogbureke kU, et al., Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 2008; 8: 212-26.
11. Hayashi C, Rittling S, Hayata T, et al., Serum osteopontin, an enhancer of tumor metastasis to bone, promotes b16 melanoma cell migration. J Cell Biochem 2007; 101: 979-86.
12. Papotti M, Kalebic T, Volante M, et al., Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. J Clin Oncol 2006; 24: 4818.
13. Karadag A, Ogbureke kU, Fedarko NS, et al., Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 2004; 96: 956-65.
14. Ibrahim T, Leong I, Sanchez-Sweatman O, et al., Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis 2000; 18: 253-60.
15. Zhang L, Hou X, Lu S, et al., Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study. Lung Cancer 2010; 67: 114-9.
16. Hou X, Zhao C, Guo Y, et al., Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol (R Coll Radiol) 2011; 23: 128-33.
17. Valverde P, Tu Q, Chen J,. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. J Bone Miner Res 2005; 20: 1669-79.
18. Khan SA, Cook AC, Kappil M, et al., Enhanced cell surface cd44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin Exp Metastasis 2005; 22: 663-73.
19. Sharp JA, Waltham M, Williams ED, et al., Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice. Clin Exp Metastasis 2004; 21: 19-29.
20. Tuck AB, Chambers AF, Allan AL,. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 2007; 102: 859-68.
21. Bucciarelli E, Sidoni A, Bellezza G, et al., Low dentin matrix protein 1 expression correlates with skeletal metastases development in breast cancer patients and enhances cell migratory capacity in vitro. Breast Cancer Res Treat 2007; 105: 95-104.
22. Carlinfante G, Vassiliou D, Svensson O, et al., Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 2003; 20: 437-44.
23. Khodavirdi AC, Song Z, Yang S, et al., Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 2006; 66: 883-8.
24. Furger KA, Allan AL, Wilson SM, et al., Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res 2003; 1: 810-9.
25. Das R, Mahabeleshwar GH, Kundu GC,. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem 2004; 279: 11051-64.
26. Cui R, Takahashi F, Ohashi R, et al., Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 2007; 57: 302-10.
27. Tang H, Wang J, Bai F, et al., Inhibition of osteopontin would suppress angiogenesis in gastric cancer. Biochem Cell Biol 2007; 85: 103-10.
28. Kang Y, Siegel PM, Shu W, et al., A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-49.
29. Shevde LA, Das S, Clark DW, et al., Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 2010; 10: 71-81.
30. Agnihotri R, Crawford HC, Haro H, et al., Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001; 276: 28261-7.
31. Modolo F, Biz MT, Martins MT, et al., Expression of extracellular matrix proteins in adenomatoid odontogenic tumor. J Oral Pathol Med 2010; 39: 230-5.
32. Chellaiah MA, Kizer N, Biswas R, et al., Osteopontin deficiency produces osteoclast dysfunction due to reduced cd44 surface expression. Mol Biol Cell 2003; 14: 173-89.
33. Bellahcène A, Menard S, Bufalino R, et al., Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 1996; 69: 350-3.
34. Waltregny D, Bellahcène A, Van Riet I, et al., Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 1998; 90: 1000-8.
35. Coleman R, Cameron D, Dodwell D, et al., Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 2014; 15: 997-1006.
36. Rodrigues P, Hering FO, Meller A,. Adjuvant effect of IV clodronate on the delay of bone metastasis in high-risk prostate cancer patients: a prospective study. Cancer Res Treat 2011; 43: 231-5.